secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001104659-26-023288
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M
--------------------------------------------------------------------------------

- Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).
- Cash and restricted cash $18.9M at Dec 31, 2025 ($58.8M year-end 2024); January 2026 raised $22.5M via stock offering led by RTW Investments.
- OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa completed enrollment (140 patients); topline data expected Q1 2027.
- OCU410ST Phase 2/3 GARDian trial nearing enrollment completion; interim data Q3 2026; OCU410 Phase 2 showed 46% lesion growth reduction.
- Exclusive Korean rights to OCU400 licensed to Kwangdong Pharmaceutical with upfront fees and milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/0001104659-26-023288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-023288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer